查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153493

2026-2034年陣發性睡眠性血尿症（PNH）治療全球市場規模、佔有率、趨勢和成長分析報告

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球陣發性睡眠性血尿症(PNH) 治療市場預計將從 2025 年的 54.6 億美元成長至 2034 年的 148.6 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 11.77%。 PNH 治療市場正經歷著顯著的進步，這主要得益於人們對該疾病認知的加深以及標靶治療的開發。 PNH 是一種罕見且嚴重的血尿症，其特徵是紅血球破壞，由於其複雜性，傳統上治療難度很高。然而，近年來單株抗體療法（例如補體抑制劑）的突破性進展徹底改變了該疾病的治療，顯著改善了患者的治療效果和生活品質。

陣發性睡眠性血紅蛋白尿症 (PNH) 的盛行率不斷上升，加上醫療專業人員對該疾病的認知不斷提高，推動了對有效治療方法的需求。診斷技術的進步使得更多患者能夠被識別和治療，進一步促進了市場發展。此外，正在進行的臨床試驗和研究計畫致力於探索聯合治療和新型療法，並有望拓寬 PNH 的治療範圍。這種對創新的重視對於滿足現有療法療效不佳患者的未滿足需求至關重要。

此外，對個人化醫療的日益重視也對發性睡眠性血紅素尿症（PNH）治療市場產生影響。基於個別患者特徵和基因標記客製化治療方案正變得越來越可行，從而實現更有效、更具針對性的治療。製藥公司與研究機構之間的合作正在加速下一代療法的研發，旨在提高療效並最大限度地減少副作用。總之，在創新、公眾意識的提高以及為改善這一複雜治療領域患者預後所做的努力的推動下，PNH治療市場預計將迎來強勁成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球陣發性睡眠性血尿症（PNH）治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 補體抑制劑
  • 鐵補充療法
  • 免疫抑制劑
  • 骨髓移植
  • 其他

第5章 全球陣發性睡眠性血尿症（PNH）治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外

第6章：全球陣發性睡眠性血尿症（PNH）治療市場：依年齡層分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第7章 全球陣發性睡眠性血尿症(PNH) 治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 居家照護環境
  • 其他

第8章 全球陣發性睡眠性血尿症(PNH) 治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AstraZeneca/Alexion
    • Novartis
    • Apellis Pharmaceuticals
    • Samsung Bioepis
    • Amgen
    • Sandoz
    • Regeneron Pharmaceuticals
    • Biogen
簡介目錄
Product Code: VMR11210464

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 14.86 Billion in 2034 from USD 5.46 Billion in 2025, growing at a CAGR of 11.77% during 2026-2034.The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.

The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.

Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-use

  • Hospitals
  • Specialty clinics
  • Homecare settings
  • Others

COMPANIES PROFILED

  • AstraZeneca/Alexion, Novartis, Apellis Pharmaceuticals, Samsung Bioepis, Amgen, Sandoz, Regeneron Pharmaceuticals, Biogen

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Iron Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Immunosuppressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Bone Marrow Transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Homecare settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Treatment Type
    • 8.2.2 By Route Of Administration
    • 8.2.3 By Age Group
    • 8.2.4 By End-use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Treatment Type
    • 8.3.2 By Route Of Administration
    • 8.3.3 By Age Group
    • 8.3.4 By End-use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Spain
    • 8.3.10 Russia
    • 8.3.11 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Treatment Type
    • 8.4.2 By Route Of Administration
    • 8.4.3 By Age Group
    • 8.4.4 By End-use
    • 8.4.5 China
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 India
    • 8.4.9 Australia
    • 8.4.10 South East Asia
    • 8.4.11 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Treatment Type
    • 8.5.2 By Route Of Administration
    • 8.5.3 By Age Group
    • 8.5.4 By End-use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Treatment Type
    • 8.6.2 By Route Of Administration
    • 8.6.3 By Age Group
    • 8.6.4 By End-use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AstraZeneca/Alexion
    • 10.2.2 Novartis
    • 10.2.3 Apellis Pharmaceuticals
    • 10.2.4 Samsung Bioepis
    • 10.2.5 Amgen
    • 10.2.6 Sandoz
    • 10.2.7 Regeneron Pharmaceuticals
    • 10.2.8 Biogen